Foghorn therapeutics to present new preclinical data at 2024 aacr annual meeting, reflecting advances with multiple potential first-in-class medicines, including the selective inhibitor of brm, fhd-909

Poster presentation of fhd-909, a first-in-class oral brm selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of nsclc; ind filing planned in q2 2024
FHTX Ratings Summary
FHTX Quant Ranking